Every day, doctors in Poland detect cancer in about 300 people, and 220 other people die from cancers a day. According to IARC, 18.1 million people fell ill in 2018 and 9.6 million people died of cancer. One in five men and every sixth woman will have cancer at some point in their lives. Despite the progress of medicine, the average number of cures in Europe is 50-60 %, while in Poland it is only 31-50 %. As the cost of illness increases, the cost of developing new oncological drugs, causing severe side effects due to imprecise effects, destroys both cancerous and healthy cells of the body. The aim of the project FiLeClo Sp. z o.o. is to receive a new substance, a salinomycin derivative with a high therapeutic potential, intended for use in oncological treatment. On the basis of preliminary scientific and experimental results, we estimate that the newly obtained compound will have a high anti-proliferation activity against selected types of cancer cells with clear selectivity towards pathological cells and allow for much more effective oncotherapy than currently used cytostatics in medicine. As part of the project, the necessary laboratory analyses will be carried out to select a candidate for a medicine and a formulation of the medicine will be developed to ensure that clinical trials can be conducted using the selected substance. Reference_Aid_programme: SA.41471(2015/X) Purpose_public_aid: Article: 25 of Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty Urz. EU L 187/1 of 26.06.2014).